483 filings
Page 21 of 25
CORRESP
gsffqzl4xxklsxpfi
17 Mar 08
Correspondence with SEC
12:00am
CORRESP
z0odmdl1jn5306bpu
5 Mar 08
Correspondence with SEC
12:00am
8-K
kbpeu956bqxltzq
3 Mar 08
Regulation FD Disclosure
12:00am
8-K
ecpqmu1x 0ng72ti40t
28 Feb 08
Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
12:00am
8-K
aal8r6ngpf0ptpjj52xd
25 Feb 08
Regulation FD Disclosure
12:00am
S-8
ek6ktjy9
8 Feb 08
Registration of securities for employees
12:00am
8-K
qqsfs0zwqqw
5 Feb 08
Alexza Initiates AZ-007 (Staccato®Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
12:00am
CORRESP
4x2p0
10 Jan 08
Correspondence with SEC
12:00am
8-K
1m302497
9 Jan 08
Departure of Directors or Principal Officers
12:00am
8-K
5hf5l72vl33
28 Dec 07
Alexza Announces Partnership with Endo for AZ-003 (Staccato®fentanyl) in North America
12:00am
8-K
uinkz6amnswhsvwz91
21 Dec 07
Alexza Elects Dr. Hal V. Barron to its Board of Directors
12:00am
UPLOAD
k7on72na
21 Dec 07
Letter from SEC
12:00am
8-K
uod0e kul8k
6 Nov 07
Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato®System
12:00am
8-K
z54zoh0d6p9
1 Nov 07
Alexza Reports Third Quarter Financial Results and Updates Development of Product Candidates
12:00am
8-K
3lcj g2t6r1pyjzt9z6
22 Oct 07
Departure of Directors or Principal Officers
12:00am
8-K
ep5l5f k4fx5i
19 Sep 07
Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato®Loxapine) in Late Q1 2008
12:00am
8-K
cz42l3
10 Sep 07
Entry into a Material Definitive Agreement
12:00am
8-K
8l4pp
13 Aug 07
Alexza Reports Second Quarter Financial Results and Updates Development of Product Candidates
12:00am